Sign up to save your podcasts
Or
Share Aging platelets shift to proinflammatory function; Odronextamab bispecific antibody therapy after CAR T in DLBCL; prizlon-cel, a novel bispecific CAR T, in B-NHL
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Aging platelets shift to proinflammatory function; Odronextamab bispecific antibody therapy after CAR T in DLBCL; prizlon-cel, a novel bispecific CAR T, in B-NHL
In this week's episode we'll learn about tracking the functional profile of aging platelets. Researchers demonstrate that over time, platelet function shifts away from hemostasis and toward a more immunomodulatory role. These finding could have important implications for transfusion medicine and certain platelet-related disease states. After that, use of odronextamab, a CD20×CD3 bispecific antibody, in patients with diffuse large B-cell lymphoma, or DLBCL, progressing after CAR T cell therapy. The study is the first to evaluate the efficacy and safety of this therapy in the post-CAR T cell treatment setting. Finally, we will recap findings from a study of a novel CAR T-cell product that utilizes specificity to two antigens common in diffuse large B-cell lymphoma.
Featured Articles:
- Aging platelets shift their hemostatic properties to inflammatory functions
- Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study
- Dissection of single-cell landscapes for the development of chimeric antigen receptor T cells in Hodgkin lymphoma
View all episodes
By American Society of Hematology
4.1
4848 ratings
In this week's episode we'll learn about tracking the functional profile of aging platelets. Researchers demonstrate that over time, platelet function shifts away from hemostasis and toward a more immunomodulatory role. These finding could have important implications for transfusion medicine and certain platelet-related disease states. After that, use of odronextamab, a CD20×CD3 bispecific antibody, in patients with diffuse large B-cell lymphoma, or DLBCL, progressing after CAR T cell therapy. The study is the first to evaluate the efficacy and safety of this therapy in the post-CAR T cell treatment setting. Finally, we will recap findings from a study of a novel CAR T-cell product that utilizes specificity to two antigens common in diffuse large B-cell lymphoma.
Featured Articles:
- Aging platelets shift their hemostatic properties to inflammatory functions
- Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study
- Dissection of single-cell landscapes for the development of chimeric antigen receptor T cells in Hodgkin lymphoma
More shows like Blood Podcast
View all
JAMA Editors' Summary
130 Listeners
Hematologic Oncology Update
72 Listeners
NEJM This Week
320 Listeners
The Hematologist
26 Listeners
JAMA Clinical Reviews
492 Listeners
Mayo Clinic Talks
273 Listeners
VJHemOnc Podcast
2 Listeners
Annals On Call Podcast
186 Listeners
The Curious Clinicians
362 Listeners
The BSH Guidelines Official Podcast
3 Listeners
EHA Unplugged
2 Listeners
WolverHeme Happy Hour
29 Listeners
Two Onc Docs
165 Listeners
Blood Cancer Talks
48 Listeners
HemeTalks: Conversations in Hematology Education
1 Listeners